Patents by Inventor Paul Gibbons

Paul Gibbons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12071425
    Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: August 27, 2024
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Cuong Q. Ly, Georgette Castanedo, Paul Gibbons, Wendy Lee, Joachim Rudolph, Nicole Alice Blaquiere, Jacob Bradley Schwarz, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Leo Fu
  • Publication number: 20240150364
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: November 13, 2023
    Publication date: May 9, 2024
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
  • Patent number: 11795170
    Abstract: Compounds of Formula (I): salts thereof and methods of making and use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: October 24, 2023
    Assignee: Genentech, Inc.
    Inventors: Mark Zak, Terry Kellar, Paul Gibbons
  • Patent number: 11731943
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: August 22, 2023
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • Publication number: 20230206644
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, Paul GIBBONS, Yun-Xing CHENG, Simon Charles GOODACRE
  • Publication number: 20230159555
    Abstract: Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.
    Type: Application
    Filed: July 21, 2022
    Publication date: May 25, 2023
    Applicant: Genentech, Inc.
    Inventors: Paul GIBBONS, Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Bing-Yan ZHU, Huifen CHEN
  • Publication number: 20230057166
    Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 23, 2023
    Inventors: Marie-Gabrielle Braun, Cuong Q. Ly, Georgette Castanedo, Paul Gibbons, Wendy Lee, Joachim Rudolph, Nicole Alice Blaquiere, Jacob Bradley Schwarz, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Leo Fu
  • Publication number: 20230047209
    Abstract: Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.
    Type: Application
    Filed: July 2, 2021
    Publication date: February 16, 2023
    Inventors: Marie-Gabrielle Braun, Georgette Castanedo, Paul Gibbons, Joachim Rudolph, William Vernier, Ramsay Beveridge, Yao Wu, Guosheng Wu
  • Publication number: 20220389020
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: January 14, 2022
    Publication date: December 8, 2022
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
  • Publication number: 20220249487
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
    Type: Application
    Filed: December 10, 2021
    Publication date: August 11, 2022
    Inventors: Marie-Gabrielle Braun, Georgette Castanedo, Paul Gibbons, Joachim Rudolph, Yao Wu, Guosheng Wu
  • Publication number: 20220204517
    Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: March 9, 2022
    Publication date: June 30, 2022
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Paul Gibbons, Terry Kellar, Wei Li, Rohan Mendonca, Po-wai Yuen, Mark Edward Zak, Lei Zhang
  • Patent number: 11279735
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: March 22, 2022
    Assignee: Genentech, Inc.
    Inventors: Emily J. Hanan, Georgette Castanedo, Marie Gabrielle Braun, Keira Garland, Peter Andrew Smith, Richard Pastor, Paul Gibbons, Yunxing Cheng, Guosheng Wu, Yuhong Fu, Po-Wai Yuen
  • Publication number: 20220048888
    Abstract: Described herein are phenoxy-pyridazinyl-pyrimidine or phenoxy-pyrimidinyl-pyrimidine compounds and pharmaceutically acceptable salts thereof for use in the treatment of Ire1-mediated diseases and cancer.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 17, 2022
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Q. Ly, Joachim Rudolph, Jacob Bradley Schwarz, Avi Ashkenazi, Ramsay Beveridge, Liang Zhao, Alexandre Lemire, Leo Fu, Kwong Wah Lai, Fei Wang
  • Patent number: 11155557
    Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: F. Anthony Romero, Mark Zak, Guiling Zhao, Paul Gibbons, Wei Li, Yun-Xing Cheng, Po-Wai Yuen, Limin Cheng
  • Patent number: 11129832
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph P. Lyssikatos, Alan G. Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • Publication number: 20210179564
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 17, 2021
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • Patent number: 10968203
    Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 6, 2021
    Assignees: Genentech, Inc., The Regents of the University of California
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Ly, Joachim Rudolph, Jacob Schwarz, Avi Ashkenazi, Leo Fu, Tommy Lai, Fei Wang, Ramsay Beveridge, Liang Zhao
  • Publication number: 20210009599
    Abstract: Compounds of Formula (I): salts thereof and methods of making and use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 14, 2021
    Applicant: Genentech, Inc.
    Inventors: Mark Zak, Terry Kellar, Paul Gibbons
  • Publication number: 20200339604
    Abstract: Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: July 13, 2020
    Publication date: October 29, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, Paul GIBBONS, Yun-Xing CHENG, Simon Charles GOODACRE
  • Publication number: 20200331968
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: March 12, 2020
    Publication date: October 22, 2020
    Applicant: Genentech, Inc.
    Inventors: Emily J. HANAN, Georgette CASTANEDO, Marie Gabrielle BRAUN, Keira GARLAND, Peter Andrew SMITH, Richard PASTOR, Paul GIBBONS, Yunxing CHENG, Guosheng WU, Yuhong FU, Po-Wai YUEN